| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/NRD3937 |
| P698 | PubMed publication ID | 23449308 |
| P2093 | author name string | Louis M Staudt | |
| Ryan M Young | |||
| P2860 | cites work | Autoimmune and Chronic Inflammatory Disorders and Risk of Non-Hodgkin Lymphoma by Subtype | Q63353115 |
| Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma. | Q64912866 | ||
| Differential binding activity of ARH1/TAM motifs | Q72349677 | ||
| DNA fiber fluorescence in situ hybridization analysis of immunoglobulin class switching in B-cell neoplasia: aberrant CH gene rearrangements in follicle center-cell lymphoma | Q77381088 | ||
| A closer look at follicular lymphoma | Q79776234 | ||
| MYD88 somatic mutation is a genetic feature of primary cutaneous diffuse large B-cell lymphoma, leg type | Q83863643 | ||
| MYD88 somatic mutations in MALT lymphomas | Q84233301 | ||
| Activation of phospholipase Cgamma2 by tyrosine phosphorylation | Q24304729 | ||
| T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20 | Q24307779 | ||
| The B-cell antigen receptor signals through a preformed transducer module of SLP65 and CIN85 | Q24319764 | ||
| Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain | Q24321955 | ||
| Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls | Q24570128 | ||
| Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia | Q24599100 | ||
| A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma | Q24607479 | ||
| Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma | Q24613755 | ||
| The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy | Q24633214 | ||
| mTOR signaling in growth control and disease | Q24634174 | ||
| PKC beta regulates BCR-mediated IKK activation by facilitating the interaction between TAK1 and CARMA1 | Q24646391 | ||
| Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia | Q24675399 | ||
| MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. | Q27851888 | ||
| Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling | Q27860529 | ||
| Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases | Q28118717 | ||
| Essential role of Src-family protein tyrosine kinases in NF-kappaB activation during B cell development | Q28206720 | ||
| Prostate stem cell antigen is overexpressed in prostate cancer metastases | Q28243809 | ||
| Agammaglobulinemia | Q28244575 | ||
| Phosphoinositide 3-kinase: diverse roles in immune cell activation | Q28251487 | ||
| Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia | Q28255147 | ||
| Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling | Q28272891 | ||
| Oncogenically active MYD88 mutations in human lymphoma | Q28301648 | ||
| Four tyrosine residues in phospholipase C-gamma 2, identified as Btk-dependent phosphorylation sites, are required for B cell antigen receptor-coupled calcium signaling | Q28571577 | ||
| Characterization of the B lymphocyte populations in Lyn-deficient mice and the role of Lyn in signal initiation and down-regulation | Q28584704 | ||
| Integrin signaling in neutrophils and macrophages uses adaptors containing immunoreceptor tyrosine-based activation motifs | Q28585779 | ||
| Syk protein-tyrosine kinase is regulated by tyrosine-phosphorylated Ig alpha/Ig beta immunoreceptor tyrosine activation motif binding and autophosphorylation | Q28615635 | ||
| Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma | Q28649793 | ||
| Induction of apoptosis in fibroblasts by c-myc protein | Q29614346 | ||
| Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia | Q29614659 | ||
| Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors | Q29615065 | ||
| PI3K pathway alterations in cancer: variations on a theme | Q29615530 | ||
| Predominant autoantibody production by early human B cell precursors | Q29619656 | ||
| Systematic review: regression of lymphoproliferative disorders after treatment for hepatitis C infection. | Q31154023 | ||
| Malignant pirates of the immune system | Q37936211 | ||
| Human follicular lymphoma cells contain oligomannose glycans in the antigen-binding site of the B-cell receptor. | Q38306094 | ||
| The PI3K isoforms p110alpha and p110delta are essential for pre-B cell receptor signaling and B cell development. | Q38341764 | ||
| Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis | Q39450233 | ||
| SYK inhibition and response prediction in diffuse large B-cell lymphoma | Q39453213 | ||
| Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas | Q39591482 | ||
| CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability | Q39642145 | ||
| The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia | Q39722770 | ||
| Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. | Q39809953 | ||
| PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia. | Q39890986 | ||
| Oncogenic CARD11 mutations in human diffuse large B cell lymphoma | Q40005246 | ||
| Regulation of Btk by Src family tyrosine kinases | Q40019232 | ||
| Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. | Q40465454 | ||
| Defective B cell development and function in Btk-deficient mice | Q41306033 | ||
| Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice | Q41541610 | ||
| PI3 kinase signals BCR-dependent mature B cell survival | Q41886641 | ||
| Burkitt's lymphoma is a malignancy of mature B cells expressing somatically mutated V region genes | Q41940816 | ||
| Anergic responses characterize a large fraction of human autoreactive naive B cells expressing low levels of surface IgM. | Q42104679 | ||
| Selective utilization of Toll-like receptor and MyD88 signaling in B cells for enhancement of the antiviral germinal center response | Q42227086 | ||
| Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells | Q42446777 | ||
| The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling | Q42475847 | ||
| Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases | Q42610807 | ||
| The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis | Q43035602 | ||
| Multiple layers of B cell memory with different effector functions | Q43255281 | ||
| Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia | Q44189657 | ||
| Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. | Q45899999 | ||
| Developmental toxicity associated with receptor tyrosine kinase Ret inhibition in reproductive toxicity testing | Q46183731 | ||
| Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer | Q47372605 | ||
| Ig gene diversification and selection in follicular lymphoma, diffuse large B cell lymphoma and primary central nervous system lymphoma revealed by lineage tree and mutation analyses. | Q51639481 | ||
| Burst-enhancing role of the IgG membrane tail as a molecular determinant of memory. | Q52014781 | ||
| In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. | Q52192552 | ||
| Impaired expansion of mouse B cell progenitors lacking Btk. | Q52507966 | ||
| The isotype of the BCR as a surrogate for the GCB and ABC molecular subtypes in diffuse large B-cell lymphoma. | Q54392737 | ||
| Leukemia and auto-immunization- some possible relationships. | Q55037357 | ||
| A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma. | Q55044497 | ||
| Essential function for the GTPase TC21 in homeostatic antigen receptor signaling. | Q55052017 | ||
| Antigen receptor tail clue. | Q55060334 | ||
| Incidence of potential glycosylation sites in immunoglobulin variable regions distinguishes between subsets of Burkitt's lymphoma and mucosa-associated lymphoid tissue lymphoma | Q58025679 | ||
| A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma | Q33155566 | ||
| A loss-of-function RNA interference screen for molecular targets in cancer | Q33237976 | ||
| Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma | Q33366976 | ||
| Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma | Q33374692 | ||
| Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia | Q33394487 | ||
| A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma | Q33399582 | ||
| Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity | Q33771413 | ||
| Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin | Q33849548 | ||
| Origin of chromosomal translocations in lymphoid cancer | Q33870612 | ||
| Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia | Q33873337 | ||
| Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. | Q33873343 | ||
| Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies | Q33893704 | ||
| Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape | Q33920097 | ||
| Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase | Q34001339 | ||
| Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. | Q34026194 | ||
| The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo | Q34029869 | ||
| B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression | Q34059352 | ||
| SF3B1 and other novel cancer genes in chronic lymphocytic leukemia | Q34093678 | ||
| PI3K/p110{delta} is a novel therapeutic target in multiple myeloma | Q34124937 | ||
| Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. | Q34131747 | ||
| Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target | Q34162571 | ||
| Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals | Q34184717 | ||
| Malt1-dependent RelB cleavage promotes canonical NF-kappaB activation in lymphocytes and lymphoma cell lines. | Q34211312 | ||
| Pathogenesis of human B cell lymphomas | Q34245261 | ||
| Germinal centers | Q34245271 | ||
| The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia | Q34249777 | ||
| Molecular underpinning of B-cell anergy | Q34262298 | ||
| Glycosylation of surface Ig creates a functional bridge between human follicular lymphoma and microenvironmental lectins | Q34276522 | ||
| Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells. | Q34472091 | ||
| The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia | Q34542102 | ||
| R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation | Q34562439 | ||
| Antigen receptor signalling: a distinctive role for the p110delta isoform of PI3K. | Q34598995 | ||
| Oligomeric organization of the B-cell antigen receptor on resting cells | Q34623132 | ||
| Tyrosine kinases and their substrates in B lymphocytes | Q34658255 | ||
| The proteolytic activity of the paracaspase MALT1 is key in T cell activation | Q34748769 | ||
| The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications | Q35029409 | ||
| Monophosphorylation of CD79a and CD79b ITAM motifs initiates a SHIP-1 phosphatase-mediated inhibitory signaling cascade required for B cell anergy | Q35596278 | ||
| CARMA1, BCL-10 and MALT1 in lymphocyte development and activation. | Q35762426 | ||
| B cell antigen receptor signaling 101. | Q35818846 | ||
| Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma | Q35848973 | ||
| The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib | Q35925610 | ||
| BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas | Q35944690 | ||
| Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies | Q36083000 | ||
| Mechanisms of B-cell lymphoma pathogenesis | Q36085626 | ||
| Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis | Q36204234 | ||
| Enhancement and suppression of signaling by the conserved tail of IgG memory-type B cell antigen receptors | Q36229232 | ||
| Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma | Q36267192 | ||
| Bruton's tyrosine kinase links the B cell receptor to nuclear factor kappaB activation | Q36368467 | ||
| Bruton's tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement | Q36368492 | ||
| Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells | Q36369816 | ||
| Self-antigen recognition by follicular lymphoma B-cell receptors | Q36410149 | ||
| ITAM-mediated tonic signalling through pre-BCR and BCR complexes | Q36430140 | ||
| SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma | Q36445884 | ||
| PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances | Q36516932 | ||
| The CARMA1 signalosome links the signalling machinery of adaptive and innate immunity in lymphocytes | Q36634002 | ||
| The SYK tyrosine kinase: a crucial player in diverse biological functions | Q36662082 | ||
| Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics | Q36721503 | ||
| Regulation of autoreactive antibodies | Q36925329 | ||
| Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation | Q36972595 | ||
| B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. | Q37028635 | ||
| Evidence for a preformed transducer complex organized by the B cell antigen receptor | Q37446227 | ||
| Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma. | Q37446487 | ||
| Suppression of phosphatidylinositol 3,4,5-trisphosphate production is a key determinant of B cell anergy | Q37457141 | ||
| The molecular assembly and organization of signaling active B-cell receptor oligomers. | Q37631686 | ||
| Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities. | Q37801513 | ||
| Receptors, subcellular compartments and the regulation of peripheral B cell responses: the illuminating state of anergy | Q37818686 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 229-243 | |
| P577 | publication date | 2013-03-01 | |
| P1433 | published in | Nature Reviews Drug Discovery | Q45998 |
| P1476 | title | Targeting pathological B cell receptor signalling in lymphoid malignancies | |
| P478 | volume | 12 |
| Q43200018 | 4th international conference on tumor progression and therapeutic resistance: meeting report |
| Q52730895 | A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial. |
| Q28608443 | A respiratory chain controlled signal transduction cascade in the mitochondrial intermembrane space mediates hydrogen peroxide signaling |
| Q24568048 | A structurally distinct human mycoplasma protein that generically blocks antigen-antibody union |
| Q59790131 | Ablation of miR-146b in mice causes hematopoietic malignancy |
| Q37731677 | Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma |
| Q36213500 | Anti-cancer activity of withaferin A in B-cell lymphoma |
| Q48018952 | Atypical B cell receptor signaling: straddling immune diseases and cancer |
| Q47561660 | Autoimmunity checkpoints as therapeutic targets in B cell malignancies |
| Q38127513 | B cell receptor signaling in chronic lymphocytic leukemia |
| Q88090511 | B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies |
| Q38124119 | B-cell antigen receptor signaling in chronic lymphocytic leukemia: therapeutic targets and translational opportunities |
| Q38659428 | B-cell receptor pathway modulators in NHL. |
| Q34398579 | B-cell receptor signaling as a driver of lymphoma development and evolution |
| Q35218042 | B-cell receptor signaling in diffuse large B-cell lymphoma |
| Q50433449 | BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells |
| Q35140116 | BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia |
| Q38243624 | Biological networks and drug discovery--where do we stand? |
| Q34025327 | Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors |
| Q36868056 | Bortezomib for the treatment of non-Hodgkin's lymphoma |
| Q38205852 | Breaking good: the inexorable rise of BTK inhibitors in the treatment of chronic lymphocytic leukaemia. |
| Q94569352 | Btk SH2-kinase interface is critical for allosteric kinase activation and its targeting inhibits B-cell neoplasms |
| Q90634678 | CD20 is dispensable for B-cell receptor signaling but is required for proper actin polymerization, adhesion and migration of malignant B cells |
| Q54940982 | Casein kinase 1α: biological mechanisms and theranostic potential. |
| Q38766227 | Catalog of genetic progression of human cancers: non-Hodgkin lymphoma. |
| Q34135450 | Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma |
| Q90316280 | Challenges and Opportunities for Childhood Cancer Drug Development |
| Q51072600 | Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells. |
| Q27027493 | Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyond |
| Q39098904 | Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow |
| Q41081977 | Clonal B cells in Waldenström's macroglobulinemia exhibit functional features of chronic active B-cell receptor signaling |
| Q42355443 | Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells |
| Q64254427 | Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma |
| Q39933783 | Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas. |
| Q38311898 | Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma. |
| Q38687541 | Comparative genomic expression signatures of signal transduction pathways and targets in paediatric Burkitt lymphoma: a Children's Oncology Group report. |
| Q42384350 | Complementarity determining region-independent recognition of a superantigen by B-cell antigen receptors of mantle cell lymphoma |
| Q38965699 | Concomitant high expression of Toll-like receptor (TLR) and B-cell receptor (BCR) signalling molecules has clinical implications in mantle cell lymphoma |
| Q40085350 | Consideration of Epstein-Barr Virus-Encoded Noncoding RNAs EBER1 and EBER2 as a Functional Backup of Viral Oncoprotein Latent Membrane Protein 1. |
| Q64026764 | Constitutive IP signaling underlies the sensitivity of B-cell cancers to the Bcl-2/IP receptor disruptor BIRD-2 |
| Q36350416 | Coordinated loss of microRNA group causes defenseless signaling in malignant lymphoma. |
| Q92887545 | Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL |
| Q54982413 | Critically dysregulated signaling pathways and clinical utility of the pathway biomarkers in lymphoid malignancies. |
| Q36226664 | DC-SIGN-expressing macrophages trigger activation of mannosylated IgM B-cell receptor in follicular lymphoma. |
| Q41765694 | Deep sequencing reveals clonal evolution patterns and mutation events associated with relapse in B-cell lymphomas |
| Q37596623 | Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue |
| Q38582791 | Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies |
| Q38714409 | Different sensitivity of germinal center B cell-like diffuse large B cell lymphoma cells towards ibrutinib treatment |
| Q33647319 | Diffuse large B cell lymphoma derived from nodular lymphocyte predominant Hodgkin lymphoma presents with variable histopathology |
| Q38161760 | Diffuse large B-cell lymphoma-treatment approaches in the molecular era. |
| Q92651431 | Digital gene expression analyses of mammary glands from meat ewes naturally infected with clinical mastitis |
| Q39031250 | Discrepant NOXA (PMAIP1) transcript and NOXA protein levels: a potential Achilles' heel in mantle cell lymphoma |
| Q42503470 | Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling |
| Q39381251 | Drug discovery and therapeutic delivery for the treatment of B and T cell tumors. |
| Q57270689 | Drug-based perturbation screen uncovers synergistic drug combinations in Burkitt lymphoma |
| Q43083592 | EBV germinates lymphoma from the germinal center in a battle with T and NK cells |
| Q47598522 | EBV latent membrane protein 2A orchestrates p27kip1 degradation via Cks1 to accelerate MYC-driven lymphoma in mice |
| Q36675192 | Editing of mouse and human immunoglobulin genes by CRISPR-Cas9 system |
| Q38994639 | Effective Combination Therapies for B-cell Lymphoma Predicted by a Virtual Disease Model |
| Q38882332 | Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells |
| Q54316519 | Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory ly |
| Q36931139 | Elucidation of tonic and activated B-cell receptor signaling in Burkitt's lymphoma provides insights into regulation of cell survival |
| Q37120620 | Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial. |
| Q34353717 | Exome sequencing reveals novel mutation targets in diffuse large B-cell lymphomas derived from Chinese patients. |
| Q59817475 | Exploring the neuropsychiatric spectrum using high-content functional analysis of single-cell signaling networks |
| Q38976449 | Expression and pro-survival function of phospholipase Cγ2 in diffuse large B-cell lymphoma |
| Q37404843 | FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma. |
| Q52645845 | First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. |
| Q39221094 | Follicular lymphoma: State-of-the-art ICML workshop in Lugano 2015. |
| Q48151021 | Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma. |
| Q53303327 | From CLL to Multiple Myeloma - Spleen Tyrosine Kinase (SYK) influences multiple myeloma cell survival and migration. |
| Q50107045 | From genetics to the clinic: a translational perspective on follicular lymphoma. |
| Q36192439 | Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL. |
| Q45594363 | Functional imaging in combination with mutation status aids prediction of response to inhibiting B-cell receptor signaling in lymphoma. |
| Q92283033 | Genetic alterations and their clinical implications in DLBCL |
| Q38294626 | Genetic and molecular targets in lymphoma: implications for prognosis and treatment. |
| Q50894954 | Genetic sequencing studies in Burkitt's lymphoma: what can we learn about tumorigenesis? |
| Q36768153 | Hepatitis C virus upregulates B-cell receptor signaling: a novel mechanism for HCV-associated B-cell lymphoproliferative disorders |
| Q30433183 | High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells |
| Q39181748 | Hypoxia and B cells |
| Q38115222 | II. Therapy of DLBCL based on genomics |
| Q38723290 | Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. |
| Q48502352 | Ibrutinib for chronic lymphocytic leukemia: international experience from a named patient program |
| Q38723944 | Ibrutinib inhibits pre-BCR+ B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK. |
| Q90468316 | Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation,in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model |
| Q34352273 | Ibrutinib treatment of CLL: the cancer fights back |
| Q34289493 | Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. |
| Q51682819 | Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma. |
| Q37058203 | Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas |
| Q33424543 | Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia |
| Q36021623 | Identification of Ezrin-Radixin-Moesin proteins as novel regulators of pathogenic B-cell receptor signaling and tumor growth in diffuse large B-cell lymphoma. |
| Q54990441 | Identification of potential ibrutinib combinations in hematological malignancies using a combination high-throughput screen. |
| Q52681376 | Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach. |
| Q37632726 | Imaging and Force Recognition of Single Molecular Behaviors Using Atomic Force Microscopy |
| Q38253121 | In pursuit of a moving target: nanotherapeutics for the treatment of non-Hodgkin B-cell lymphoma |
| Q34683996 | Inhibiting CARD11 translation during BCR activation by targeting the eIF4A RNA helicase |
| Q34042407 | Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma |
| Q36217436 | Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cells |
| Q36020943 | Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma |
| Q92669992 | JNK/AP1 Pathway Regulates MYC Expression and BCR Signaling through Ig Enhancers in Burkitt Lymphoma Cells |
| Q41343171 | LRRK1 is critical in the regulation of B-cell responses and CARMA1-dependent NF-κB activation. |
| Q39016086 | Loss of function mutations in PTPN6 promote STAT3 deregulation via JAK3 kinase in diffuse large B-cell lymphoma |
| Q91411436 | MARCKS regulates tonic and chronic active B cell receptor signaling |
| Q88027873 | MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma |
| Q28081162 | Management of chronic lymphocytic leukemia (CLL) in the era of B-cell receptor signal transduction inhibitors |
| Q30240133 | Mature aggressive B-cell lymphoma across age groups - molecular advances and therapeutic implications |
| Q38413580 | Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma |
| Q92488934 | Metabolic gatekeepers to safeguard against autoimmunity and oncogenic B cell transformation |
| Q38550810 | Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment |
| Q94561521 | Missing-in-Metastasis/Metastasis Suppressor 1 Regulates B Cell Receptor Signaling, B Cell Metabolic Potential, and T Cell-Independent Immune Responses |
| Q26825394 | Molecular Pathogenesis of MALT Lymphoma |
| Q47118882 | Mutational profile of primary breast diffuse large B-cell lymphoma |
| Q54247368 | NF-κB Activation in Lymphoid Malignancies: Genetics, Signaling, and Targeted Therapy. |
| Q38178074 | NF-κB pathways in hematological malignancies |
| Q38988815 | NF-κB signaling pathway and its potential as a target for therapy in lymphoid neoplasms |
| Q48540669 | Nanoparticles-Emerging Potential for Managing Leukemia and Lymphoma. |
| Q41522612 | Negative role of TAK1 in marginal zone B-cell development incidental to NF-κB noncanonical pathway activation |
| Q91283875 | New roles for B cell receptor associated kinases: when the B cell is not the target |
| Q26782270 | Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma Therapy |
| Q27304386 | Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review |
| Q90028953 | On the architecture of translational research designed to control chronic lymphocytic leukemia |
| Q55281964 | Oncogenic Signaling Pathways and Pathway-Based Therapeutic Biomarkers in Lymphoid Malignancies. |
| Q37522401 | Oncogenic mechanisms in Burkitt lymphoma |
| Q37688853 | PEITC-mediated inhibition of mRNA translation is associated with both inhibition of mTORC1 and increased eIF2α phosphorylation in established cell lines and primary human leukemia cells. |
| Q64087586 | Paralogues From the Expanded Tlr11 Gene Family in Mudskipper () Are Under Positive Selection and Respond Differently to LPS/Poly(I:C) Challenge |
| Q33433009 | Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies |
| Q38984735 | Phosphodiesterase 4 inhibitors have wide-ranging activity in B-cell malignancies |
| Q42027992 | Plasma immunoprofiling of patients with high-risk diffuse large B-cell lymphoma: a Nordic Lymphoma Group study |
| Q42399865 | Precision medicine in diffuse large B-cell lymphoma: hitting the target. |
| Q38241102 | Precision therapy for lymphoma--current state and future directions. |
| Q64263337 | Presence of serum antinuclear antibodies correlating unfavorable overall survival in patients with chronic lymphocytic leukemia |
| Q42205963 | Prevalence of targetable oncogenic mutations and genomic alterations in Epstein-Barr virus-associated diffuse large B-cell lymphoma of the elderly |
| Q38345576 | Prognosis and therapy of chronic lymphocytic leukemia and small lymphocytic lymphoma |
| Q48316610 | Rational Targeting of Cellular Cholesterol in Diffuse Large B-Cell Lymphoma (DLBCL) Enabled by Functional Lipoprotein Nanoparticles: A Therapeutic Strategy Dependent on Cell of Origin |
| Q35723998 | Rationale for targeting the pre-B-cell receptor signaling pathway in acute lymphoblastic leukemia |
| Q53730905 | Rationale for targeting tumor cells in their microenvironment for mantle cell lymphoma treatment. |
| Q47228609 | Regulation of gammaherpesvirus lytic replication by endoplasmic reticulum stress-induced transcription factors ATF4 and CHOP. |
| Q38831146 | Rewired NFκB signaling as a potentially actionable feature of activated B-cell-like diffuse large B-cell lymphoma. |
| Q26795594 | Role of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell Neoplasms |
| Q36988095 | Role of the CARMA1/BCL10/MALT1 complex in lymphoid malignancies |
| Q38567094 | Roles of the NF-κB Pathway in B-Lymphocyte Biology. |
| Q36250522 | Rosette Assay: Highly Customizable Dot-Blot for SH2 Domain Screening |
| Q39472422 | Safety and Pharmacodynamics of the PDE4 Inhibitor Roflumilast in Advanced B-cell Malignancies |
| Q36201677 | Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia |
| Q47709959 | Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. |
| Q36161658 | Specificity and biologic activities of novel anti-membrane IgM antibodies |
| Q58610265 | Spleen tyrosine kinase (SYK) protects renal tubular epithelial cell against hypoxia injury in children with acute kidney injury |
| Q36091288 | Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib |
| Q47300115 | Synergistic targeting of the regulatory and catalytic subunits of PI3Kδ in mature B cell malignancies |
| Q35850333 | Systems-wide analysis of BCR signalosomes and downstream phosphorylation and ubiquitylation. |
| Q40279273 | TET2 mutation in diffuse large B-cell lymphoma. |
| Q51767473 | Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma. |
| Q103037431 | Targeted in vivo delivery of NF-κB decoy inhibitor augments sensitivity of B-cell lymphoma to therapy |
| Q40716705 | Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. |
| Q49951221 | Targeting B cell receptor signalling in cancer: preclinical and clinical advances |
| Q92158076 | Targeting B-cell receptor signaling in leukemia and lymphoma: how and why? |
| Q90573731 | Targeting Bcl-2-IP3 receptor interaction to treat cancer: A novel approach inspired by nearly a century treating cancer with adrenal corticosteroid hormones |
| Q36334833 | Targeting Bruton's tyrosine kinase signaling as an emerging therapeutic agent of B-cell malignancies |
| Q100945782 | Targeting N-myristoylation for therapy of B-cell lymphomas |
| Q38744922 | Targeting of B-cell receptor signalling in B-cell malignancies. |
| Q36120391 | The B-cell antigen receptor integrates adaptive and innate immune signals |
| Q50968575 | The B-cell receptor controls fitness of MYC-driven lymphoma cells via GSK3β inhibition |
| Q26822700 | The B-cell receptor orchestrates environment-mediated lymphoma survival and drug resistance in B-cell malignancies |
| Q28083266 | The biology behind PI3K inhibition in chronic lymphocytic leukaemia |
| Q33709463 | The effects of DLEU1 gene expression in Burkitt lymphoma (BL): potential mechanism of chemoimmunotherapy resistance in BL |
| Q48319540 | The genomic landscape of two Burkitt lymphoma cases and derived cell lines: comparison between primary and relapse samples. |
| Q37392612 | The histone methyltransferase EZH2 as a novel prosurvival factor in clinically aggressive chronic lymphocytic leukemia. |
| Q26865760 | The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy |
| Q38460308 | The pre-B-cell receptor checkpoint in acute lymphoblastic leukaemia. |
| Q35939776 | The pre-BCR to the rescue: therapeutic targeting of pre-B cell ALL. |
| Q38891634 | The synergistic effect of BCR signaling inhibitors combined with an HDAC inhibitor on cell death in a mantle cell lymphoma cell line |
| Q27687567 | The tumor microenvironment shapes hallmarks of mature B-cell malignancies |
| Q64929215 | Transcriptional Regulation in the Immune System: One Cell at a Time. |
| Q41691918 | Ubiquilin1 promotes antigen-receptor mediated proliferation by eliminating mislocalized mitochondrial proteins. |
| Q33587128 | Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma |
| Q53185261 | [Current treatment strategies for follicular lymphoma]. |
Search more.